[Cefotetan in the treatment of sinusitis--a kinetic study].
Recent clinical experience shows that in treating sinusitis by tetracyclines more and more cases appear which are resistant to therapy. Cephalosporins are suitable as alternative medical treatment because of their good bactericidal effect. The pharmacokinetic qualities of Cefotetan, a new cephamycin-antibiotic, in plasma and sinus mucosa were examined in treating 13 patients. After an intravenous bolus-injection of 2 g Cefotetan the mean initial plasma concentration was 275 mg/l. After 1, 2 and 6 hours the plasma levels were 160, 96 and 39 mg/l. The average concentration in sinus mucosa reached 42.3 mg/l, 30.9 mg/l, 29.4 mg/l and 33.6 mg/l after 10, 60, 120 and 180 minutes. The pharmacokinetic properties of Cefotetan promise successful clinical application in the treatment of bacterial sinusitis.
D000328:Adult; D015313:Cefotetan; D002513:Cephamycins / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009092:Mucous Membrane / Q000378:metabolism; D010256:Paranasal Sinuses / Q000378:metabolism; D012852:Sinusitis / Q000097:blood / Q000188:drug therapy*
D002513:Cephamycins; D015313:Cefotetan
Cefotetan zur Behandlung der Sinusitis--Eine kinetische Studie.